News | July 08, 2022
ALPLA acquires Polish packaging manufacturer APON
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Subscribe To Our Newsletter & Stay Updated
